FI3981437T3 - Nukleiinihapporokotteita - Google Patents
Nukleiinihapporokotteita Download PDFInfo
- Publication number
- FI3981437T3 FI3981437T3 FIEP21191353.8T FI21191353T FI3981437T3 FI 3981437 T3 FI3981437 T3 FI 3981437T3 FI 21191353 T FI21191353 T FI 21191353T FI 3981437 T3 FI3981437 T3 FI 3981437T3
- Authority
- FI
- Finland
- Prior art keywords
- virus
- vaccine
- human
- infection
- cationic lipid
- Prior art date
Links
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title claims 3
- 229940023146 nucleic acid vaccine Drugs 0.000 title claims 3
- 229960005486 vaccine Drugs 0.000 claims 13
- -1 cationic lipid Chemical class 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 238000007385 chemical modification Methods 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 claims 1
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims 1
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims 1
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 claims 1
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 claims 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 claims 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010060931 Adenovirus infection Diseases 0.000 claims 1
- 241001302512 Banna virus Species 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241000702669 Coltivirus Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 241000190708 Guanarito mammarenavirus Species 0.000 claims 1
- 206010069767 H1N1 influenza Diseases 0.000 claims 1
- 241000893570 Hendra henipavirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241001479210 Human astrovirus Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000046923 Human bocavirus Species 0.000 claims 1
- 241001207270 Human enterovirus Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000342334 Human metapneumovirus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000702617 Human parvovirus B19 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000712890 Junin mammarenavirus Species 0.000 claims 1
- 241000712902 Lassa mammarenavirus Species 0.000 claims 1
- 241000712898 Machupo mammarenavirus Species 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000526636 Nipah henipavirus Species 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- 241000702259 Orbivirus Species 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 229930185560 Pseudouridine Natural products 0.000 claims 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000192617 Sabia mammarenavirus Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983250P | 2014-04-23 | 2014-04-23 | |
| US201462088994P | 2014-12-08 | 2014-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3981437T3 true FI3981437T3 (fi) | 2025-01-10 |
Family
ID=54333225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21191353.8T FI3981437T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
| FIEP21195046.4T FI4023249T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21195046.4T FI4023249T3 (fi) | 2014-04-23 | 2015-04-23 | Nukleiinihapporokotteita |
Country Status (23)
Families Citing this family (301)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| PT4223311T (pt) | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| LT2717893T (lt) | 2011-06-08 | 2019-08-12 | Translate Bio, Inc. | Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| CA2892391C (en) | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| AU2014236305B2 (en) | 2013-03-14 | 2019-01-17 | Ethris Gmbh | CFTR mRNA compositions and related methods and uses |
| PL2970456T3 (pl) | 2013-03-14 | 2022-01-31 | Translate Bio, Inc. | Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna |
| MX2015012865A (es) | 2013-03-14 | 2016-07-21 | Shire Human Genetic Therapies | Metodos para purificacion de arn mensajero. |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| PL4332576T3 (pl) | 2013-03-15 | 2025-09-08 | Translate Bio, Inc. | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| CA2912307C (en) * | 2013-06-11 | 2022-01-11 | Biocartis Nv | Biomolecule drying process for long-term storage |
| PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) * | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| ES2954366T3 (es) | 2013-10-22 | 2023-11-21 | Translate Bio Inc | Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa |
| CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| MX373952B (es) | 2014-04-25 | 2020-07-13 | Shire Human Genetic Therapies | Métodos de purificación de arn mensajero. |
| US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
| IL298516B2 (en) | 2014-06-25 | 2025-03-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| EP3169335B8 (en) | 2014-07-16 | 2019-10-09 | ModernaTX, Inc. | Circular polynucleotides |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| CA2990202A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP4218805A1 (en) * | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017019935A1 (en) * | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Multimeric mrna |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4101930A1 (en) | 2015-09-17 | 2022-12-14 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| CN108473969B9 (zh) | 2015-10-14 | 2024-08-23 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
| AU2016342049B2 (en) * | 2015-10-22 | 2023-05-18 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| CN118846026A (zh) | 2015-10-22 | 2024-10-29 | 摩登纳特斯有限公司 | 广谱流感病毒疫苗 |
| SMT202300052T1 (it) | 2015-10-28 | 2023-05-12 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per il rilascio di acidi nucleici |
| US10851136B2 (en) * | 2015-11-19 | 2020-12-01 | Creation Plus Biotechnology Co. Ltd | Recombinant lactic acid bacteria and the use thereof in oral universal influenza vaccine |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US11246920B2 (en) | 2016-03-03 | 2022-02-15 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| ES2844180T3 (es) | 2016-04-08 | 2021-07-21 | Translate Bio Inc | Acido nucleico codificante multimérico y usos del mismo |
| EP3448364B1 (en) | 2016-04-29 | 2022-02-09 | Icahn School of Medicine at Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3024917A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| AU2017268394A1 (en) | 2016-05-18 | 2019-01-03 | Modernatx, Inc. | Polynucleotides encoding relaxin |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| ES2941411T3 (es) | 2016-05-18 | 2023-05-22 | Modernatx Inc | Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos |
| CA3024507A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease |
| AU2017283479B2 (en) | 2016-06-13 | 2023-08-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
| WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
| CN115404196A (zh) * | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| EP3493834A1 (en) * | 2016-08-07 | 2019-06-12 | Novartis AG | Mrna-mediated immunization methods |
| CN116115629A (zh) | 2016-08-17 | 2023-05-16 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3519428A4 (en) | 2016-10-03 | 2020-07-08 | Duke University | METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2017347837A1 (en) * | 2016-10-26 | 2019-06-06 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| US20200163878A1 (en) * | 2016-10-26 | 2020-05-28 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| EP3532097A1 (en) * | 2016-10-27 | 2019-09-04 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| EP3538146A4 (en) * | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| MX2019008303A (es) | 2017-01-11 | 2019-12-02 | Univ Pennsylvania | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. |
| SG11201906895WA (en) | 2017-02-01 | 2019-08-27 | Modernatx Inc | Rna cancer vaccines |
| AU2018214556A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CN107300583A (zh) * | 2017-04-18 | 2017-10-27 | 武汉博沃生物科技有限公司 | 疫苗中蔗糖含量的检测方法及其应用 |
| MA49463A (fr) * | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
| WO2018200892A1 (en) * | 2017-04-27 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS |
| EP3615510B1 (en) | 2017-04-28 | 2024-03-27 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
| WO2018222986A1 (en) * | 2017-06-02 | 2018-12-06 | Shackelton Laura | Genetically attenuated nucleic acid vaccine |
| WO2018222983A1 (en) | 2017-06-02 | 2018-12-06 | Shackelton Laura | Phenotypically wild-type and genetically attenuated viruses |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| JP7461872B2 (ja) | 2017-08-17 | 2024-04-04 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| US20200254086A1 (en) * | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CN111655280B (zh) | 2017-09-01 | 2025-01-14 | 达纳-法伯癌症研究所股份有限公司 | 用于治疗癌症的bcma和taci抗原特异的免疫原性肽 |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| KR20250093420A (ko) * | 2017-09-29 | 2025-06-24 | 인텔리아 테라퓨틱스, 인크. | 게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법 |
| US11773144B2 (en) | 2017-10-02 | 2023-10-03 | Duke University | Mosaic HIV-1 envelopes to induce ADCC responses |
| KR20250138817A (ko) * | 2017-10-19 | 2025-09-22 | 큐어백 에스이 | 신규 인공 핵산 분자 |
| GB201718660D0 (en) * | 2017-11-10 | 2017-12-27 | Ucl Business Plc | Improved liposome for mRNA delivery to cells |
| CA3083102A1 (en) * | 2017-11-21 | 2019-05-31 | Modernatx, Inc. | Epstein-barr virus vaccines |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| EP3724208A4 (en) | 2017-12-15 | 2021-09-01 | Flagship Pioneering Innovations VI, LLC | COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES |
| EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| WO2019126144A1 (en) | 2017-12-22 | 2019-06-27 | North Carolina State University | Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same |
| EP3735264A1 (en) * | 2018-01-05 | 2020-11-11 | Rolf Jonas Andreas Nilsson | Endogenous tumor-derived circular rna and proteins thereof for use as vaccine |
| US11447775B2 (en) | 2018-01-12 | 2022-09-20 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| MX2020007439A (es) | 2018-01-12 | 2020-09-14 | Bristol Myers Squibb Co | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos. |
| US11911453B2 (en) * | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| EP3752185A1 (en) | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
| CN108424881B (zh) * | 2018-03-23 | 2021-07-27 | 中国食品药品检定研究院 | 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用 |
| TWI682779B (zh) * | 2018-04-03 | 2020-01-21 | 林淑卿 | 豬疾病疫苗用佐劑及其製備方法 |
| CN108324941A (zh) * | 2018-04-03 | 2018-07-27 | 林淑卿 | 猪疾病疫苗用佐剂及其制备方法 |
| ES3001512T3 (en) * | 2018-04-29 | 2025-03-05 | Global Life Sciences Solutions Canada Ulc | Compositions for transfecting resistant cell types |
| EP3794008A1 (en) * | 2018-05-16 | 2021-03-24 | Translate Bio, Inc. | Ribose cationic lipids |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| MA53102B1 (fr) | 2018-07-03 | 2025-11-28 | Fennec Pharmaceuticals, Inc. | Formulations de thiosulfate de sodium anhydre |
| CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| JP7425066B2 (ja) | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
| EP3846857A4 (en) * | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| CN112996854B (zh) * | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CA3113449A1 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| IL281135B2 (en) | 2018-09-28 | 2024-12-01 | Nutcracker Therapeutics Inc | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
| US12138304B2 (en) | 2018-10-01 | 2024-11-12 | Duke University | HIV-1 envelope stabilizing mutations |
| EP3860637A4 (en) * | 2018-10-01 | 2022-08-17 | Duke University | COMPOSITIONS WITH HIV ENVELOPES FOR INDUCING HIV-1 ANTIBODIES |
| WO2020077007A1 (en) * | 2018-10-09 | 2020-04-16 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| US12042527B2 (en) | 2019-01-08 | 2024-07-23 | Modernatx, Inc. | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| IL284535B2 (en) | 2019-01-11 | 2025-03-01 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active ingredients |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| KR20210149727A (ko) | 2019-03-11 | 2021-12-09 | 모더나티엑스, 인크. | 유가식(fed-batch) 시험관내 전사 공정 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| WO2020198403A2 (en) | 2019-03-25 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
| CN109880835B (zh) * | 2019-03-28 | 2022-03-25 | 扬州大学 | 重组h9n2禽流感病毒株、其制备方法、禽流感疫苗及其应用 |
| CN114040782A (zh) * | 2019-04-30 | 2022-02-11 | 威斯康星州医药大学股份有限公司 | 跨鼓膜递送平台及其用途 |
| IL288284B2 (en) | 2019-05-22 | 2024-06-01 | Massachusetts Inst Technology | Circular rna compositions and methods |
| MA56535A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
| EP4027982A1 (en) * | 2019-09-11 | 2022-07-20 | ModernaTX, Inc. | Lnp-formulated mrna therapeutics and use thereof for treating human subjects |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| CN110897032B (zh) * | 2019-11-19 | 2025-10-14 | 华南理工大学 | 一种发酵饲料蛋白及其制备方法与应用 |
| JP2023504568A (ja) | 2019-12-04 | 2023-02-03 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| WO2021118976A1 (en) | 2019-12-09 | 2021-06-17 | University Of Georgia Research Foundation, Inc. | M. tuberculosis ag85 proteins and methods of use |
| EP4087619A4 (en) * | 2020-01-07 | 2024-02-21 | Translate Bio MA, Inc. | FORMULATIONS FOR THE DELIVERY OF OLIGONUCLEOTIDES TO LUNG CELLS |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP4100052A2 (en) * | 2020-02-07 | 2022-12-14 | ModernaTX, Inc. | Sars-cov-2 mrna domain vaccines |
| CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| KR20230004447A (ko) * | 2020-02-14 | 2023-01-06 | 이더알엔에이 이뮤노테라피스 엔브이 | 비강 내 mRNA 백신 |
| CN111378785A (zh) * | 2020-03-12 | 2020-07-07 | 仁宽(上海)生物科技有限公司 | 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用 |
| GB2605312B (en) | 2020-03-23 | 2024-06-26 | Hdt Bio Corp | Compositions and methods for delivery of RNA |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| EP4132478A1 (en) | 2020-04-09 | 2023-02-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| KR102813425B1 (ko) | 2020-04-22 | 2025-05-28 | 바이오엔테크 에스이 | 코로나바이러스 백신 |
| WO2021229448A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Rna replicon encoding a stabilized corona virus spike protein |
| CN111647557A (zh) * | 2020-05-18 | 2020-09-11 | 中国人民解放军第四军医大学 | 一种表面偶联s蛋白的外泌体及其制备方法和应用 |
| CN113679701B (zh) * | 2020-05-18 | 2024-04-30 | 中国科学院上海药物研究所 | 邻苯三酚及其衍生物作为共价配体反应弹头的用途 |
| WO2021236855A1 (en) * | 2020-05-19 | 2021-11-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| AU2021275223A1 (en) * | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| CN116322758A (zh) * | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| CN115605221A (zh) * | 2020-06-11 | 2023-01-13 | 第一三共株式会社（Jp） | 核酸脂质粒子疫苗 |
| CN111714621B (zh) * | 2020-06-29 | 2021-04-27 | 中国科学院昆明动物研究所 | 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022015513A2 (en) | 2020-07-13 | 2022-01-20 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods to assess rna stability |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| BR112023001563A2 (pt) * | 2020-07-31 | 2023-10-10 | Combined Therapeutics Inc | Composições e métodos para vacinação melhorada |
| US20220031836A1 (en) * | 2020-08-03 | 2022-02-03 | Avalon GloboCare Corp. | Emulsomes comprising s-layer fusion proteins and methods of use thereof |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022047427A2 (en) | 2020-08-31 | 2022-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for producing rna constructs with increased translation and stability |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| WO2022091119A1 (en) * | 2020-10-26 | 2022-05-05 | Gunjan Kumar | A pharmaceutical kit comprising copper sulfate and ascorbic acid |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| CN112358545B (zh) * | 2020-11-10 | 2022-03-01 | 中国农业大学 | 鸽毛滴虫与白色念珠菌二联卵黄抗体粉的制备方法及应用 |
| WO2022108937A2 (en) * | 2020-11-17 | 2022-05-27 | Phosphorex, Inc. | Novel drug delivery composition and process for blood-brain barrier crossing |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| GB202019916D0 (en) * | 2020-12-16 | 2021-01-27 | Imperial College Innovations Ltd | RNA vaccine |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US12263217B2 (en) | 2020-12-23 | 2025-04-01 | Daykin Molecular Systems, LLC | Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20240066119A1 (en) * | 2021-01-13 | 2024-02-29 | University Of Maryland, College Park | Methods and platforms for eliciting an immune response in the treatment of cancer and compositions and vaccines relating thereto |
| AU2022208057A1 (en) * | 2021-01-15 | 2023-08-03 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CA3210497A1 (en) * | 2021-03-08 | 2022-09-15 | Robert O.Iii Williams | Dry powder formulations of nucleic acid lipid nanoparticles |
| WO2022198101A1 (en) | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
| US11260113B1 (en) | 2021-03-26 | 2022-03-01 | King Abdulaziz University | NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| CN117642179A (zh) | 2021-05-19 | 2024-03-01 | 第一三共株式会社 | 流感病毒核酸脂质颗粒疫苗 |
| EP4342491A4 (en) | 2021-05-19 | 2025-08-20 | Nat Inst Biomedical Innovation Health & Nutrition | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE |
| CN113476598A (zh) * | 2021-07-20 | 2021-10-08 | 武汉圣润生物科技有限公司 | 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用 |
| US12251471B2 (en) | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| WO2023008881A1 (ko) * | 2021-07-29 | 2023-02-02 | 주식회사 에스엠엘바이오팜 | 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물 |
| EP4387597A1 (en) * | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| US20250134824A1 (en) * | 2021-08-16 | 2025-05-01 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| JP2024535351A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | 乾燥ナノ粒子組成物 |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| AU2022349251A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Sars-cov-2 rna vaccine compositions and methods of use |
| AU2022351009A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| EP4412592A4 (en) * | 2021-10-06 | 2025-11-19 | Seqirus Inc | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN |
| CA3237658A1 (en) * | 2021-10-08 | 2023-04-13 | Pfizer Inc. | Immunogenic lnp compositions and methods thereof |
| US20250281583A1 (en) | 2021-10-13 | 2025-09-11 | Modernatx, Inc. | Composition of mrna-encoded il15 fusion proteins and methods of use thereof |
| KR20240090727A (ko) | 2021-10-22 | 2024-06-21 | 세일 바이오메디슨스, 인크. | Mrna 백신 조성물 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023104904A2 (en) | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
| CN115813848B (zh) * | 2021-12-10 | 2023-08-08 | 上海臻上医药科技有限公司 | 微针注射mRNA编码双特异性抗体药物的试剂、方法和应用 |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
| EP4452282A4 (en) * | 2021-12-22 | 2025-10-29 | Terence Francis Mullins | SYSTEM AND METHOD FOR ANTIBODY ACTIVATORS IN AN AQUEOUS IODINE SOLUTION |
| WO2023133500A2 (en) * | 2022-01-07 | 2023-07-13 | Hdt Bio Corp. | Compositions and methods for multivalent immune responses |
| CN114437237B (zh) * | 2022-01-12 | 2023-10-24 | 黑龙江八一农垦大学 | 金黄色葡萄球菌trap靶向重组蛋白抗原及其用途 |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN115304756B (zh) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | 一种五元脂质纳米颗粒及其制备方法和应用 |
| JP2025508467A (ja) | 2022-02-24 | 2025-03-26 | アイオー バイオテック エーピーエス | 癌治療のヌクレオチド送達 |
| KR20250005214A (ko) | 2022-04-13 | 2025-01-09 | 우니버시타트 아우토노마 데 바르셀로나 | 클로토 단백질을 발현시키는 유전자 요법을 통한 신경근 질환의 치료 |
| CN116942610A (zh) * | 2022-04-29 | 2023-10-27 | 北京祥瑞生物制品股份有限公司 | 一种核酸药物递送系统及其制备方法 |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| CN114591386B (zh) * | 2022-05-10 | 2022-09-09 | 深圳厚存纳米药业有限公司 | 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| EP4296274A1 (en) | 2022-06-23 | 2023-12-27 | Universidade de Santiago de Compostela | Peptides for intracellular delivery |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024020453A2 (en) * | 2022-07-20 | 2024-01-25 | Hdt Bio Corp. | Immune system modulators and uses thereof |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| GB202216449D0 (en) | 2022-11-04 | 2022-12-21 | Io Biotech Aps | TGF-BETA1 vaccine |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN118272396A (zh) | 2022-12-29 | 2024-07-02 | 仁景(苏州)生物科技有限公司 | 用于预防或治疗hpv感染相关疾病的多核苷酸分子 |
| WO2024159172A1 (en) | 2023-01-27 | 2024-08-02 | Senda Biosciences, Inc. | A modified lipid composition and uses thereof |
| EP4410316A1 (en) * | 2023-02-01 | 2024-08-07 | 4basebio UK Ltd | Nanoparticles for delivery of nucleic acid cargos |
| WO2024178305A1 (en) | 2023-02-24 | 2024-08-29 | Modernatx, Inc. | Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| AU2024234874A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| WO2024238881A1 (en) * | 2023-05-17 | 2024-11-21 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating candida auris infection |
| WO2024254518A2 (en) * | 2023-06-07 | 2024-12-12 | Nvelop Therapeutics, Inc. | Compositions of lipid delivery particles and method of use thereof |
| WO2025006263A2 (en) * | 2023-06-27 | 2025-01-02 | Cz Biohub Sf, Llc | Design of universal influenza vaccine candidates via antigen reorientation |
| WO2025007148A1 (en) * | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| WO2025049959A2 (en) | 2023-09-01 | 2025-03-06 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| US20250073334A1 (en) * | 2023-09-05 | 2025-03-06 | The Regents Of The University Of California | Injectable hydrogel for sustained co-delivery of an antigen and an adjuvant, and uses thereof |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
| WO2025219454A1 (en) | 2024-04-18 | 2025-10-23 | Poltreg S.A. | Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes |
| WO2025231407A1 (en) * | 2024-05-03 | 2025-11-06 | Nutech Ventures | Lipid nanoparticles and methods of making and using |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| CN119424376B (zh) * | 2025-01-13 | 2025-07-25 | 北京大学 | 一种可超声靶向的脂质纳米颗粒及其应用 |
Family Cites Families (482)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0204401A1 (en) | 1985-04-09 | 1986-12-10 | Biogen, Inc. | Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
| EP0802980A1 (en) | 1994-06-02 | 1997-10-29 | Chiron Corporation | Nucleic acid immunization using a virus-based infection/transfection system |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6111095A (en) | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| EP0912607A2 (en) | 1996-06-21 | 1999-05-06 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| US5939262A (en) | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5989911A (en) | 1997-05-09 | 1999-11-23 | University Of Massachusetts | Site-specific synthesis of pseudouridine in RNA |
| JP2002508299A (ja) | 1997-09-19 | 2002-03-19 | セクイター， インク． | センスｍＲＮＡ治療 |
| EP1021548A1 (en) | 1997-10-07 | 2000-07-26 | University Of Maryland Biotechnology Institute | Method for introducing and expressing rna in animal cells |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
| US20090017533A1 (en) | 1998-09-29 | 2009-01-15 | Shire Human Genetic Therapies, Inc., A Delaware Corporation | Optimized messenger rna |
| CA2364921A1 (en) | 1999-02-22 | 2000-08-31 | European Molecular Biology Laboratory | Translation system |
| WO2000029561A2 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
| ATE289630T1 (de) | 1999-09-09 | 2005-03-15 | Curevac Gmbh | Transfer von mrnas unter verwendung von polykationischen verbindungen |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| AU7725500A (en) | 1999-09-30 | 2001-04-30 | National Jewish Medical And Research Center | Method for inhibition of pathogenic microorganisms |
| AU2001275423B2 (en) | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
| GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US7776523B2 (en) | 2000-12-07 | 2010-08-17 | Novartis Vaccines And Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| DE50211110D1 (de) | 2001-04-21 | 2007-12-06 | Curevac Gmbh | INJEKTIONSGERÄT FÜR mRNA APPLIKATION |
| EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| ES2354607T3 (es) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| TW200403338A (en) | 2002-07-16 | 2004-03-01 | Advisys Inc | Codon optimized synthetic plasmids |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| TW200515917A (en) | 2003-09-15 | 2005-05-16 | Us Government | Methods and compositions for the generation of a protective immune response against SARS-COV |
| AU2004279362B2 (en) | 2003-09-15 | 2011-03-17 | Genvec, Inc. | HIV vaccines based on ENV of multiple clades of HIV |
| US20050065114A1 (en) | 2003-09-23 | 2005-03-24 | Jean-Claude Yvin | Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| AU2005248361B2 (en) * | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| US8663599B1 (en) | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| WO2006074341A2 (en) | 2005-01-07 | 2006-07-13 | Glaxo Group Limited | Novel use |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US20120021042A1 (en) | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2628300C (en) * | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| US8603457B2 (en) | 2005-12-02 | 2013-12-10 | University Of Rochester | Nonsense suppression and genetic codon alteration by targeted modification |
| ES2564241T3 (es) | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanopartículas para su uso en composiciones inmunogénicas |
| US7767210B2 (en) | 2005-12-14 | 2010-08-03 | The Board Of Regents Of The University Of Oklahoma | RNA virus vaccines and methods |
| DK1976871T3 (da) | 2006-01-13 | 2011-12-12 | Univ Pennsylvania | Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| EP2397123A1 (en) | 2006-07-07 | 2011-12-21 | Aarhus Universitet | Nanoparticles for nucleic acid delivery |
| CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
| KR101586968B1 (ko) * | 2006-08-09 | 2016-01-20 | 메디뮨 엘엘씨 | 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체 |
| EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| US20090088331A1 (en) * | 2006-11-07 | 2009-04-02 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And | Influenza virus nucleic acid microarray and method of use |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| CN101611145B (zh) | 2006-12-21 | 2013-08-14 | 诺维信股份有限公司 | 用于在细菌细胞中表达基因的修饰型信使rna稳定化序列 |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| US8057804B2 (en) | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP2450372B1 (en) | 2007-01-30 | 2015-04-22 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2008109712A2 (en) | 2007-03-05 | 2008-09-12 | Washington University | Nanoparticle delivery systems for membrane-integrating peptides |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| US7682789B2 (en) | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
| DK2826863T3 (en) | 2007-05-30 | 2017-12-04 | Univ Northwestern | NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS |
| EP3040082A1 (en) | 2007-05-31 | 2016-07-06 | Statens Serum Institut | Influenza vaccines |
| US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009039198A2 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of The University Of Pennsylvania | Generation of hyperstable mrnas |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| WO2009046388A1 (en) | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| EP2394657A1 (en) | 2007-10-12 | 2011-12-14 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| WO2009062348A1 (en) | 2007-11-14 | 2009-05-22 | Institute Of Microbiology, Chinese Academy Of Sciences | Methods for inhibiting influenza virus infection and their drugs |
| US8081186B2 (en) | 2007-11-16 | 2011-12-20 | Microsoft Corporation | Spatial exploration field of view preview mechanism |
| US9226959B2 (en) | 2008-01-31 | 2016-01-05 | Curevac Ag | Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| US20120027813A1 (en) | 2008-02-22 | 2012-02-02 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines for pediatric use |
| WO2009119722A1 (ja) * | 2008-03-28 | 2009-10-01 | 国立大学法人北海道大学 | 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体 |
| CA2721333C (en) * | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| WO2010009065A2 (en) | 2008-07-15 | 2010-01-21 | Novartis Ag | Amphipathic peptide compositions |
| JP5781929B2 (ja) | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| AU2015210364B2 (en) | 2008-10-09 | 2017-03-09 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US20100112042A1 (en) | 2008-10-16 | 2010-05-06 | Mdrna, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
| CA3006395C (en) | 2008-11-07 | 2022-05-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| PL2355851T3 (pl) | 2008-11-10 | 2018-08-31 | Arbutus Biopharma Corporation | Nowe lipidy i kompozycje do dostarczania środków terapeutycznych |
| WO2010060430A2 (en) | 2008-11-28 | 2010-06-03 | Statens Serum Institut | Optimized influenza vaccines |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| EP2401365B1 (en) | 2009-02-24 | 2016-04-27 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
| US8460696B2 (en) | 2009-03-20 | 2013-06-11 | Egen, Inc. | Polyamine derivatives |
| EP2421563B1 (en) | 2009-04-22 | 2017-04-12 | Massachusetts Institute of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| US8883202B2 (en) | 2009-05-05 | 2014-11-11 | Tekmira Pharmaceuticals Corporation | Lipid compositions |
| LT2440183T (lt) | 2009-06-10 | 2018-08-10 | Arbutus Biopharma Corporation | Patobulinta lipido kompozicija |
| MX2011013421A (es) | 2009-06-15 | 2012-03-16 | Alnylam Pharmaceuticals Inc | Arnds formulado con lipido de direccionamiento del gen pcsk9. |
| US9732337B2 (en) | 2009-06-16 | 2017-08-15 | The United Stated of America, as represented by the Secretary, Department of Health & Human Services | RNA nanoparticles and nanotubes |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| EP2459231B1 (de) | 2009-07-31 | 2016-06-08 | Ethris Gmbh | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2011017548A1 (en) | 2009-08-05 | 2011-02-10 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| MX343908B (es) | 2009-08-26 | 2016-11-28 | Selecta Biosciences Inc * | Composiciones que inducen la ayuda de las células t. |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CA2816925C (en) | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| KR102505097B1 (ko) | 2009-12-07 | 2023-03-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제 |
| EP2512449B1 (en) | 2009-12-18 | 2019-08-07 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20110184160A1 (en) | 2010-01-26 | 2011-07-28 | Weiner David B | Nucleic acid molecule encoding consensus influenza a hemagglutinin h1 |
| US9089537B2 (en) | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| EP3391877A1 (en) * | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| EP3072961A1 (en) | 2010-04-16 | 2016-09-28 | Children's Medical Center Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US9254327B2 (en) | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| JP2013531634A (ja) | 2010-05-24 | 2013-08-08 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質 |
| CN105194665A (zh) | 2010-05-26 | 2015-12-30 | 西莱克塔生物科技公司 | 具有不偶合的佐剂的纳米载体组合物 |
| JP5957646B2 (ja) | 2010-06-04 | 2016-07-27 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質 |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| SI2590676T1 (sl) | 2010-07-06 | 2016-11-30 | Glaxosmithkline Biologicals, S.A. | Virionu podobni delci za dajanje za samorepliciranje RNA molekul |
| SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
| PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
| CN107648604A (zh) | 2010-07-30 | 2018-02-02 | 库瑞瓦格股份公司 | 聚合物载体运载物复合物及聚合物载体的用途 |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| AU2011291522A1 (en) | 2010-08-20 | 2013-01-24 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| MX2013002173A (es) | 2010-08-23 | 2013-05-06 | Selecta Biosciences Inc | Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos. |
| WO2012030901A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Small liposomes for delivery of immunogen-encoding rna |
| CN103384515B (zh) | 2010-08-31 | 2017-02-15 | 诺华有限公司 | 适用于脂质体递送编码蛋白质的rna的脂质 |
| SI3970742T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo RNA, ki kodira imunogen |
| ES2908978T3 (es) | 2010-08-31 | 2022-05-04 | Sirna Therapeutics Inc | Nuevas entidades químicas simples y métodos para la administración de oligonucleótidos |
| RU2617641C2 (ru) | 2010-09-20 | 2017-04-25 | Сирна Терапьютикс,Инк. | Новые низкомолекулярные катионные липиды для доставки олигонуклеотидов |
| EP2621480B1 (en) | 2010-09-30 | 2018-08-15 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| BR112013008700B8 (pt) | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| CN103153347A (zh) | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| KR101939150B1 (ko) | 2010-11-12 | 2019-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| MX344972B (es) | 2010-11-16 | 2017-01-12 | Selecta Biosciences Inc | Oligonucleotidos inmunoestimulantes. |
| WO2012072096A1 (en) | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012092569A2 (en) | 2010-12-31 | 2012-07-05 | Selecta Biosciences, Inc. | Compositions comprising immunostimulatory nucleic acids and related methods |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| US20120189700A1 (en) | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
| US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
| WO2012116715A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| JP6054308B2 (ja) | 2011-02-15 | 2016-12-27 | メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 核酸を細胞へ送達する組成物及び方法 |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012138453A1 (en) | 2011-04-03 | 2012-10-11 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| KR101998431B1 (ko) | 2011-04-26 | 2019-07-09 | 몰레큘라 익스프레스 인코포레이티드 | 리포솜 제제 |
| US9579283B2 (en) | 2011-04-28 | 2017-02-28 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| EP2710136A4 (en) | 2011-05-17 | 2015-01-21 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND USE METHOD FOR NON-HUMAN SPINE |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| PT4223311T (pt) | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| DK2714017T3 (en) | 2011-06-02 | 2018-09-03 | Univ California | MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE |
| LT2717893T (lt) | 2011-06-08 | 2019-08-12 | Translate Bio, Inc. | Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai |
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| CN106995488A (zh) | 2011-06-20 | 2017-08-01 | 高等教育联邦系统-匹兹堡大学 | 计算优化的宽反应性的h1n1流感抗原 |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| SG10201605537XA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US9008142B2 (en) | 2011-07-22 | 2015-04-14 | Insight Photonic Solutions, Inc. | System and method for optimization of coherence length of tunable laser sources |
| US9018089B2 (en) | 2011-08-30 | 2015-04-28 | International Business Machines Corporation | Multiple step anneal method and semiconductor formed by multiple step anneal |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| BR112014005103A2 (pt) | 2011-09-02 | 2017-07-04 | Novartis Ag | composições orgânicas para tratar doenças associadas com hsf1 |
| EP3384938A1 (en) * | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN108164602A (zh) * | 2011-09-20 | 2018-06-15 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| CA2849822C (en) | 2011-09-23 | 2021-05-11 | Gary J. Nabel, M.D. | Novel influenza hemagglutinin protein-based vaccines |
| WO2013049328A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| DK2768958T3 (da) | 2011-10-18 | 2019-09-16 | Dicerna Pharmaceuticals Inc | Kationiske aminlipider og anvendelser deraf |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
| MX363409B (es) | 2011-11-03 | 2019-03-20 | Sentinext Therapeutics Sdn Bhd | Antigenos y vacunas dirigidos contra enterovirus hunanos. |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| SI2773326T1 (sl) | 2011-11-04 | 2019-04-30 | Nitto Denko Corporation | Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| WO2013075266A1 (en) * | 2011-11-23 | 2013-05-30 | Vacdiagn Biotechnology Co., Ltd. | Immune methods against influenza viruses and combinatorial vaccines thereof |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| JP6182458B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質の組み合わせを含有する脂質ナノ粒子 |
| TWI594767B (zh) | 2011-12-12 | 2017-08-11 | 協和醱酵麒麟有限公司 | 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子 |
| WO2013090186A1 (en) * | 2011-12-14 | 2013-06-20 | modeRNA Therapeutics | Modified nucleic acids, and acute care uses thereof |
| US20140378538A1 (en) | 2011-12-14 | 2014-12-25 | Moderma Therapeutics, Inc. | Methods of responding to a biothreat |
| US9636414B2 (en) | 2011-12-15 | 2017-05-02 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| CA2859691A1 (en) | 2011-12-21 | 2013-06-27 | Moderna Therapeutics, Inc. | Methods of increasing the viability or longevity of an organ or organ explant |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| AU2013231638B2 (en) | 2012-03-16 | 2017-10-12 | Merck Patent Gmbh | Targeting aminoacid lipids |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9717685B2 (en) | 2012-03-26 | 2017-08-01 | President And Fellows Of Harvard College | Lipid-coated nucleic acid nanostructures of defined shape |
| CA2866955A1 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
| ES2858523T3 (es) | 2012-03-29 | 2021-09-30 | Translate Bio Inc | Nanopartículas neutras derivadas de lípidos |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| HK1210479A1 (en) | 2012-04-10 | 2016-04-22 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| TWI654997B (zh) | 2012-06-08 | 2019-04-01 | 日商日東電工股份有限公司 | 用於治療劑輸送配方之脂質 |
| US10245229B2 (en) * | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
| US10231997B2 (en) | 2012-08-15 | 2019-03-19 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| CN104812372A (zh) | 2012-10-04 | 2015-07-29 | 约翰内斯堡金山大学 | 脂质体药物递送系统 |
| CA2890110C (en) | 2012-11-01 | 2023-05-02 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| TW201920677A (zh) | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| JP6353846B2 (ja) | 2012-11-09 | 2018-07-04 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | 細胞のｒｎａ発現方法 |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| WO2014089486A1 (en) | 2012-12-07 | 2014-06-12 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
| WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| CN104902925A (zh) | 2013-01-10 | 2015-09-09 | 诺华股份有限公司 | 流感病毒免疫原性组合物及其应用 |
| MX385338B (es) | 2013-02-22 | 2025-03-18 | CureVac SE | Combinación de vacunación e inhibición de la trayectoria pd-1. |
| JP6352950B2 (ja) | 2013-03-08 | 2018-07-04 | ノバルティス アーゲー | 活性薬物の送達のための脂質と脂質組成物 |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3431592A1 (en) | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| PL2970456T3 (pl) | 2013-03-14 | 2022-01-31 | Translate Bio, Inc. | Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna |
| CN105283548A (zh) | 2013-03-15 | 2016-01-27 | 葛兰素史密斯克莱生物公司 | Rna纯化方法 |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| US10342760B2 (en) | 2013-03-15 | 2019-07-09 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP2968523A4 (en) | 2013-03-15 | 2016-07-20 | Univ Pennsylvania | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MANUFACTURED THEREOF |
| EP2968530A4 (en) | 2013-03-15 | 2016-04-06 | Univ Pennsylvania | Vaccines with biomolecular adjuvants |
| PL4332576T3 (pl) | 2013-03-15 | 2025-09-08 | Translate Bio, Inc. | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane |
| US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| EP2978848B1 (en) | 2013-03-28 | 2020-05-06 | Medicago Inc. | Influenza virus-like particle production in plants |
| EP2994167B1 (en) | 2013-05-06 | 2020-05-06 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
| WO2014210356A1 (en) | 2013-06-26 | 2014-12-31 | Massachusetts Institute Of Technology | Multi-tailed lipids and uses thereof |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
| CN105555757A (zh) | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
| JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質 |
| WO2015023461A2 (en) | 2013-08-06 | 2015-02-19 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| MX2016002152A (es) | 2013-08-21 | 2017-01-05 | Curevac Ag | Metodo para aumentar la expresion de proteinas codificadas por arn. |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
| EP3871696B1 (en) | 2013-10-22 | 2025-03-19 | Translate Bio, Inc. | Lipid formulations for delivery of messenger rna |
| EP2883872A1 (en) | 2013-12-16 | 2015-06-17 | Universite De Bordeaux I | Five-membered cyclic biscarbonates bearing amide linkages, their preparation and their uses for the preparation of polyhydroxyurethanes |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
| IL298516B2 (en) | 2014-06-25 | 2025-03-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3169783A4 (en) | 2014-07-17 | 2018-10-03 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| CN107427571A (zh) | 2014-12-31 | 2017-12-01 | 美利坚合众国,由健康及人类服务部部长代表 | 基于纳米颗粒的新型多价疫苗 |
| EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
| WO2016201377A1 (en) | 2015-06-10 | 2016-12-15 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| WO2016203025A1 (en) | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| US11364292B2 (en) * | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017019935A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Multimeric mrna |
| US20180237849A1 (en) | 2015-08-17 | 2018-08-23 | Modernatx, Inc. | Rna mapping/fingerprinting |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| EP4424835A3 (en) | 2015-09-21 | 2024-10-23 | TriLink BioTechnologies, LLC | Compositions and methods for synthesizing 5'-capped rnas |
| ES2810701T5 (es) | 2015-10-05 | 2024-07-11 | Modernatx Inc | Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| US20180318409A1 (en) | 2015-10-22 | 2018-11-08 | Modernatx, Inc. | Cancer vaccines |
| EP4349405A3 (en) * | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| JP7687767B2 (ja) | 2015-10-22 | 2025-06-03 | モデルナティエックス インコーポレイテッド | 呼吸器合胞体ウイルスワクチン |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| AU2016342049B2 (en) | 2015-10-22 | 2023-05-18 | Modernatx, Inc. | Herpes simplex virus vaccine |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| CN118846026A (zh) | 2015-10-22 | 2024-10-29 | 摩登纳特斯有限公司 | 广谱流感病毒疫苗 |
| SMT202300052T1 (it) | 2015-10-28 | 2023-05-12 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per il rilascio di acidi nucleici |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017153936A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Chemically modified messenger rna's |
| EP3452086A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Influenza mrna vaccines |
| US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| AU2017268394A1 (en) | 2016-05-18 | 2019-01-03 | Modernatx, Inc. | Polynucleotides encoding relaxin |
| MA45041A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
| ES2941411T3 (es) | 2016-05-18 | 2023-05-22 | Modernatx Inc | Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos |
| US20190382774A1 (en) | 2016-05-18 | 2019-12-19 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| JP2019519601A (ja) | 2016-05-18 | 2019-07-11 | モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． | 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3024507A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease |
| SG11201810162PA (en) | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
| WO2017201333A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia |
| WO2017201332A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
| EP3468537A1 (en) | 2016-06-14 | 2019-04-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CA3034681A1 (en) | 2016-06-30 | 2018-01-04 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger rna |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| WO2018075592A1 (en) | 2016-10-21 | 2018-04-26 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
| EP3532613A4 (en) | 2016-10-26 | 2020-05-06 | ModernaTX, Inc. | METHOD AND COMPOSITIONS FOR RNA MAPPING |
| AU2017347837A1 (en) | 2016-10-26 | 2019-06-06 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| US20200163878A1 (en) | 2016-10-26 | 2020-05-28 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| AU2017357758B2 (en) | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
| US20180243225A1 (en) | 2017-01-25 | 2018-08-30 | Modernatx, Inc. | Ebola/marburg vaccines |
| ES2905591T3 (es) | 2017-01-27 | 2022-04-11 | Methodist Hospital | Plataforma de estructura de núcleo/cáscara para inmunoterapia |
| WO2018144778A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Polynucleotide secondary structure |
| SG11201906895WA (en) | 2017-02-01 | 2019-08-27 | Modernatx Inc | Rna cancer vaccines |
| AU2018214556A1 (en) | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| WO2018157009A1 (en) | 2017-02-24 | 2018-08-30 | Modernatx, Inc. | Nucleic acid-based therapy of muscular dystrophies |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| US20200038499A1 (en) | 2017-03-22 | 2020-02-06 | Modernatx, Inc. | Rna bacterial vaccines |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| MA49463A (fr) | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| WO2018232355A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna antibodies |
| EP3655040A1 (en) | 2017-07-21 | 2020-05-27 | Modernatx, Inc. | Modified mrna encoding a propionyl-coa carboxylase and uses thereof |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
| US20200254086A1 (en) | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| EA202090919A1 (ru) | 2017-10-31 | 2020-09-09 | Модернатикс, Инк. | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a |
| US20190192646A1 (en) | 2017-11-03 | 2019-06-27 | Modernatx, Inc. | Salmonella vaccines |
| CA3083102A1 (en) | 2017-11-21 | 2019-05-31 | Modernatx, Inc. | Epstein-barr virus vaccines |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| SG11202012770RA (en) | 2018-06-27 | 2021-01-28 | Modernatx Inc | Personalized cancer vaccine epitope selection |
| CA3111836A1 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| JP2022506839A (ja) | 2018-11-07 | 2022-01-17 | モデルナティエックス インコーポレイテッド | Ｒｎａがんワクチン |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| KR20210149727A (ko) | 2019-03-11 | 2021-12-09 | 모더나티엑스, 인크. | 유가식(fed-batch) 시험관내 전사 공정 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| CA3133858A1 (en) | 2019-03-19 | 2020-09-24 | Arcturus Therapeutics, Inc. | Method of making lipid-encapsulated rna nanoparticles |
| WO2020243561A1 (en) | 2019-05-31 | 2020-12-03 | Modernatx, Inc. | Expanded t cell assay |
| BR112022002548A2 (pt) | 2019-08-14 | 2022-06-14 | Modernatx Inc | Processos para purificar produtos a jusante de transcrição in vitro |
| EP4028030A4 (en) | 2019-09-11 | 2023-09-27 | ModernaTX, Inc. | VACCINE AGAINST HUMAN CYTOMEGALOVIRUS |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| US20220349006A1 (en) | 2019-09-19 | 2022-11-03 | Moderna TX, Inc. | Cap guides and methods of use thereof for rna mapping |
| US20210217484A1 (en) | 2020-01-10 | 2021-07-15 | Modernatx, Inc. | Variational autoencoder for biological sequence generation |
| US20210228707A1 (en) | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| CN115103682A (zh) | 2020-01-30 | 2022-09-23 | 摩登纳特斯有限公司 | 呼吸道病毒免疫组合物 |
| MX2022009410A (es) | 2020-01-31 | 2022-10-18 | Modernatx Inc | Metodos de preparacion de nanoparticulas lipidicas. |
| EP4100052A2 (en) | 2020-02-07 | 2022-12-14 | ModernaTX, Inc. | Sars-cov-2 mrna domain vaccines |
| WO2021211343A1 (en) | 2020-04-13 | 2021-10-21 | Modernatx, Inc. | Zika virus mrna vaccines |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| EP4149484A4 (en) | 2020-05-15 | 2024-10-02 | ModernaTX, Inc. | RNA FORMULATIONS FOR HIGH VOLUME DELIVERY |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| US20230190761A1 (en) | 2020-05-21 | 2023-06-22 | Modernatx, Inc. | Methylene blue stabilized mrna compositions |
| US20230287437A1 (en) | 2020-06-05 | 2023-09-14 | Modernatx, Inc. | Bacterial strains for dna production |
| MX2023001461A (es) | 2020-08-06 | 2023-04-26 | Modernatx Inc | Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| CN116490166A (zh) | 2020-10-12 | 2023-07-25 | 翻译生物公司 | 制备加载mRNA的脂质纳米颗粒的改进方法 |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| EP4277653A1 (en) | 2021-01-15 | 2023-11-22 | ModernaTX, Inc. | Variant strain-based coronavirus vaccines |
| AU2022208057A1 (en) | 2021-01-15 | 2023-08-03 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| US20240100145A1 (en) | 2021-03-05 | 2024-03-28 | Moderna TX, Inc. | Vlp enteroviral vaccines |
| US20240299531A1 (en) | 2021-03-15 | 2024-09-12 | Moderna TX, Inc | Therapeutic use of sars-cov-2 mrna domain vaccines |
| US20240181038A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4313072A1 (en) | 2021-03-26 | 2024-02-07 | ModernaTX, Inc. | Pertussis vaccine |
| WO2022212442A1 (en) | 2021-03-31 | 2022-10-06 | Modernatx, Inc. | Synthesis of trinucleotide and tetranucleotide caps for mrna production |
| JP2024512780A (ja) | 2021-04-01 | 2024-03-19 | モデルナティエックス インコーポレイテッド | 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法 |
| EP4314046A4 (en) | 2021-04-01 | 2025-03-19 | ModernaTX, Inc. | Mucosal expression of antibody structures and isotypes by mRNA |
| CA3216490A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Epstein-barr virus mrna vaccines |
| WO2022221336A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory syncytial virus mrna vaccines |
| EP4322993A1 (en) | 2021-04-13 | 2024-02-21 | ModernaTX, Inc. | Respiratory virus combination vaccines |
| EP4322994A1 (en) | 2021-04-14 | 2024-02-21 | ModernaTX, Inc. | Influenza-coronavirus combination vaccines |
| WO2022226277A1 (en) | 2021-04-23 | 2022-10-27 | Modernatx, Inc. | Stabilized formulations |
| EP4326241A1 (en) | 2021-04-23 | 2024-02-28 | ModernaTX, Inc. | Isoquinoline-stabilized lipid nanoparticle formulations |
| WO2022232585A1 (en) | 2021-04-29 | 2022-11-03 | Modernatx, Inc. | Lyophilization methods for preparing lipid formulated therapeutics |
| MX2023013004A (es) | 2021-05-03 | 2023-11-15 | Pfizer | Composicion inmunogenica contra la influenza. |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
| EP4355761A1 (en) | 2021-06-14 | 2024-04-24 | ModernaTX, Inc. | Mrna vaccines encoding flexible coronavirus spike proteins |
| WO2022266012A1 (en) | 2021-06-14 | 2022-12-22 | Modernatx, Inc. | Coronavirus glycosylation variant vaccines |
| WO2022266389A1 (en) | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
| WO2023283642A2 (en) | 2021-07-09 | 2023-01-12 | Modernatx, Inc. | Pan-human coronavirus concatemeric vaccines |
| EP4366768A4 (en) | 2021-07-09 | 2025-05-21 | ModernaTX, Inc. | Pan-human coronavirus vaccines |
| WO2023283645A1 (en) | 2021-07-09 | 2023-01-12 | Modernatx, Inc. | Pan-human coronavirus domain vaccines |
| US20250092440A1 (en) | 2021-08-02 | 2025-03-20 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment |
| WO2023018773A1 (en) | 2021-08-11 | 2023-02-16 | Modernatx, Inc. | Lipid nanoparticle formulations and methods of synthesis thereof |
| WO2023019181A1 (en) | 2021-08-11 | 2023-02-16 | Modernatx, Inc. | Sars-cov-2 lipid nanoparticle vaccine formulations |
| WO2023018923A1 (en) | 2021-08-13 | 2023-02-16 | Modernatx, Inc. | Multicolumn chromatography mrna purification |
| WO2023056401A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus |
| US20250051736A1 (en) | 2021-10-18 | 2025-02-13 | Modernatx, Inc. | Custom bacterial strain for recombinant protein production |
| US20250011798A1 (en) | 2021-10-18 | 2025-01-09 | Modernatx, Inc. | Markerless dna production |
| US20250231165A1 (en) | 2021-10-20 | 2025-07-17 | Modernatx, Inc. | Drug product surrogate solutions |
| EP4423187A1 (en) | 2021-10-26 | 2024-09-04 | Exopolymer, Inc. | Heat stable and/or heat activated biopolymers |
| EP4426855A1 (en) | 2021-11-05 | 2024-09-11 | ModernaTX, Inc. | Methods of purifying dna for gene synthesis |
| WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| JP2024545152A (ja) | 2021-12-08 | 2024-12-05 | モデルナティエックス インコーポレイテッド | 単純ヘルペスウイルスｍＲＮＡワクチン |
| EP4448777A1 (en) | 2021-12-15 | 2024-10-23 | ModernaTX, Inc. | Determination of encapsulation efficiency of lipid nanoparticles |
| US20250084397A1 (en) | 2022-01-04 | 2025-03-13 | Modernatx, Inc. | Methods of purifying dna for gene synthesis |
| EP4463545A1 (en) | 2022-01-14 | 2024-11-20 | ModernaTX, Inc. | In vitro transcription dna purification and recycling |
| US20250136970A1 (en) | 2022-02-03 | 2025-05-01 | Modernatx, Inc. | Continuous precipitation for mrna purification |
| EP4475882A1 (en) | 2022-02-09 | 2024-12-18 | ModernaTX, Inc. | Mucosal administration methods and formulations |
| WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
| WO2023201204A1 (en) | 2022-04-11 | 2023-10-19 | Modernatx, Inc. | Detection of mrna purity in a mixture |
| CN119317710A (zh) | 2022-04-14 | 2025-01-14 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2023201296A1 (en) | 2022-04-15 | 2023-10-19 | Modernatx, Inc. | Ribosomal engagement potency assay |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| WO2023225524A1 (en) | 2022-05-17 | 2023-11-23 | Modernatx, Inc. | Preparation of highly concentrated mrna |
-
2015
- 2015-04-23 RS RS20250021A patent/RS66380B1/sr unknown
- 2015-04-23 SM SM20250052T patent/SMT202500052T1/it unknown
- 2015-04-23 PT PT211913538T patent/PT3981437T/pt unknown
- 2015-04-23 EP EP15783606.5A patent/EP3134131B1/en active Active
- 2015-04-23 SM SM20250053T patent/SMT202500053T1/it unknown
- 2015-04-23 EP EP24204789.2A patent/EP4501318A3/en active Pending
- 2015-04-23 SI SI201532049T patent/SI4023249T1/sl unknown
- 2015-04-23 LT LTEPPCT/US2015/027400T patent/LT3134131T/lt unknown
- 2015-04-23 JP JP2017507919A patent/JP6881813B2/ja active Active
- 2015-04-23 SG SG11201608798YA patent/SG11201608798YA/en unknown
- 2015-04-23 RS RS20250020A patent/RS66388B1/sr unknown
- 2015-04-23 ES ES21191353T patent/ES3009962T3/es active Active
- 2015-04-23 EP EP21191353.8A patent/EP3981437B1/en active Active
- 2015-04-23 CA CA2946751A patent/CA2946751A1/en active Pending
- 2015-04-23 LT LTEP21191353.8T patent/LT3981437T/lt unknown
- 2015-04-23 WO PCT/US2015/027400 patent/WO2015164674A1/en not_active Ceased
- 2015-04-23 PT PT211950464T patent/PT4023249T/pt unknown
- 2015-04-23 PT PT157836065T patent/PT3134131T/pt unknown
- 2015-04-23 RS RS20220289A patent/RS63050B1/sr unknown
- 2015-04-23 HR HRP20241733TT patent/HRP20241733T1/hr unknown
- 2015-04-23 SG SG10201912038TA patent/SG10201912038TA/en unknown
- 2015-04-23 PL PL15783606T patent/PL3134131T3/pl unknown
- 2015-04-23 BR BR112016024644A patent/BR112016024644A2/pt active Search and Examination
- 2015-04-23 ES ES21195046T patent/ES3003986T3/es active Active
- 2015-04-23 SI SI201532048T patent/SI3981437T1/sl unknown
- 2015-04-23 MA MA59052A patent/MA59052B1/fr unknown
- 2015-04-23 HU HUE21195046A patent/HUE069802T2/hu unknown
- 2015-04-23 RU RU2021109685A patent/RU2021109685A/ru unknown
- 2015-04-23 PL PL21195046.4T patent/PL4023249T3/pl unknown
- 2015-04-23 ES ES15783606T patent/ES2909180T3/es active Active
- 2015-04-23 HU HUE21191353A patent/HUE069770T2/hu unknown
- 2015-04-23 FI FIEP21191353.8T patent/FI3981437T3/fi active
- 2015-04-23 DK DK15783606.5T patent/DK3134131T3/da active
- 2015-04-23 RU RU2016145597A patent/RU2746406C2/ru active
- 2015-04-23 LT LTEP21195046.4T patent/LT4023249T/lt unknown
- 2015-04-23 SI SI201531776T patent/SI3134131T1/sl unknown
- 2015-04-23 CN CN201580033861.2A patent/CN106659803A/zh active Pending
- 2015-04-23 DK DK21195046.4T patent/DK4023249T3/da active
- 2015-04-23 PL PL21191353.8T patent/PL3981437T3/pl unknown
- 2015-04-23 FI FIEP21195046.4T patent/FI4023249T3/fi active
- 2015-04-23 SM SM20220158T patent/SMT202200158T1/it unknown
- 2015-04-23 HR HRP20220070TT patent/HRP20220070T1/hr unknown
- 2015-04-23 EP EP21195046.4A patent/EP4023249B1/en active Active
- 2015-04-23 MA MA58292A patent/MA58292B1/fr unknown
- 2015-04-23 HR HRP20241732TT patent/HRP20241732T1/hr unknown
- 2015-04-23 AU AU2015249553A patent/AU2015249553B2/en not_active Withdrawn - After Issue
- 2015-04-23 DK DK21191353.8T patent/DK3981437T3/da active
- 2015-04-23 HU HUE15783606A patent/HUE057800T2/hu unknown
- 2015-04-23 CA CA3177878A patent/CA3177878A1/en active Pending
-
2016
- 2016-04-01 US US15/089,050 patent/US10022435B2/en active Active
- 2016-04-05 US US15/091,123 patent/US9872900B2/en active Active
-
2018
- 2018-07-16 US US16/036,318 patent/US20190008948A1/en not_active Abandoned
- 2018-07-27 US US16/048,154 patent/US10709779B2/en active Active
- 2018-09-27 US US16/144,394 patent/US20190015501A1/en not_active Abandoned
-
2021
- 2021-02-05 JP JP2021017295A patent/JP7504464B2/ja active Active
- 2021-03-17 US US17/204,801 patent/US20210220467A1/en not_active Abandoned
- 2021-05-28 AU AU2021203492A patent/AU2021203492A1/en not_active Abandoned
-
2022
- 2022-02-28 US US17/683,171 patent/US20240398927A9/en not_active Abandoned
- 2022-03-18 CY CY20221100220T patent/CY1125084T1/el unknown
-
2024
- 2024-02-26 JP JP2024026489A patent/JP2024071384A/ja active Pending
- 2024-08-12 US US18/801,071 patent/US20240408191A1/en not_active Abandoned
- 2024-08-12 US US18/801,143 patent/US12274743B2/en active Active
- 2024-08-12 US US18/801,174 patent/US12329812B2/en active Active
- 2024-11-26 AU AU2024266879A patent/AU2024266879A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3981437T3 (fi) | Nukleiinihapporokotteita | |
| ZA202106848B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| JP2017518372A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537521A5 (cg-RX-API-DMAC7.html) | ||
| RU2020117033A (ru) | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение | |
| MX344879B (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| JP2009539965A5 (cg-RX-API-DMAC7.html) | ||
| MX2022015612A (es) | Nucleotidos de purina beta-d-2'-desoxi-2'-alfa-fluoro-2'-beta-c-su stituidos-2-modificados-n6-sustituidos para el tratamiento del virus de la hepatitis c. | |
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| WO2011130557A3 (en) | Phosphonates with reduced toxicity for treatment of viral infections | |
| ATE345353T1 (de) | Langwirkende fusionspeptidinhibitoren gegen hiv- infektion | |
| EA201890196A1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
| WO2012174312A3 (en) | Benzimidazole derivatives as antiviral agents | |
| BRPI0921424A2 (pt) | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. | |
| WO2010068708A3 (en) | 3'-azido purine nucleotide prodrugs for treatment of viral infections | |
| MY194471A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| WO2008124176A3 (en) | Soluble and membrane-anchored forms of lassa virus subunit proteins | |
| EA200602289A1 (ru) | Применение иматиниба для лечения нарушений работы печени и вирусных инфекций | |
| FI20030037A7 (fi) | Parapoxvirus ovis-kantojen käyttö virusvastaisten lääkkeiden ja syövän vastaisten lääkkeiden tuottamiseksi | |
| Ilina et al. | Inhibitors of HIV‐1 reverse transcriptase | |
| JP2016533190A5 (cg-RX-API-DMAC7.html) | ||
| WO2009152519A3 (en) | Novel antiviral peptides against influenza virus | |
| DK1765370T3 (da) | Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS |